Stat
- Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm
- How the pandemic has reshaped collaboration — and competition — in science
- STAT+: Teva to pay $925,000 to Mississippi to settle generic price-fixing charges
- STAT+: Key science officials detail their plans for a new research agency — and Congress is getting closer to funding it
- STAT+: Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs
NYT science news
Fierce Biotech
- After rebounding from FDA setback, uniQure goes all in on gene therapy with $55M Corlieve buy
- Meet Hugo: Medtronic’s robotic-assisted surgery system makes global debut in Chilean clinic
- Digital therapy maker Pear Therapeutics shakes the money tree, with plans to go public in $1.6B SPAC deal
- Moove over IPO: SAB Biotherapeutics to milk the stock market via SPAC
- TRexBio has Jurassic day picking up ex-Lilly VP as CEO, snagging Big Pharma funding
Fierce Medical Devices
- Meet Hugo: Medtronic’s robotic-assisted surgery system makes global debut in Chilean clinic
- Digital therapy maker Pear Therapeutics shakes the money tree, with plans to go public in $1.6B SPAC deal
- Alchemab's new well-connected CEO will lead biotech on journey to address hard-to-treat diseases
- Duke, HumanFirst launch center to ensure digital health tools are up to snuff for clinical trials
- Insilico Medicine scores $255M venture round to move AI-designed drugs into human clinical trials